Idelalisib-rituximab induces durable remissions in TP53 disrupted B-PLL but results in significant toxicity: updated results of the UK-wide compassionate use programme.
AffiliationDepartment of Haematology, Oxford University Hospitals NHS Trust, Churchill Hospital, Oxford, UK
MetadataShow full item record
CitationIdelalisib-rituximab induces durable remissions in TP53 disrupted B-PLL but results in significant toxicity: updated results of the UK-wide compassionate use programme. 2018, Br J Haematol
JournalBritish Journal of Haematology
- Idelalisib-Rituximab induces clinical remissions in patients with TP53 disrupted B cell prolymphocytic leukaemia.
- Authors: Eyre TA, Fox CP, Shankara P, Went R, Schuh AH
- Issue date: 2017 May
- Idelalisib-related pneumonitis.
- Authors: Haustraete E, Obert J, Diab S, Abbes S, Zini JM, Valade S, Lerolle N, Albin N, Arnulf B, Bouaziz JD, Hussenet C, Tazi A, Bergeron A
- Issue date: 2016 Apr
- Effective upfront treatment with low-dose ibrutinib for a patient with B cell prolymphocytic leukemia.
- Authors: Oka S, Ono K, Nohgawa M
- Issue date: 2020 Oct
- B and T cell prolymphocytic leukaemia.
- Authors: Cross M, Dearden C
- Issue date: 2019 Sep
- Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
- Authors: Smith SM, Pitcher BN, Jung SH, Bartlett NL, Wagner-Johnston N, Park SI, Richards KL, Cashen AF, Jaslowski A, Smith SE, Cheson BD, Hsi E, Leonard JP
- Issue date: 2017 Apr